A5075346486- Malaria Research and Control
- RNA Interference and Gene Delivery
- HIV Research and Treatment
- Mosquito-borne diseases and control
- Computational Drug Discovery Methods
- Advanced biosensing and bioanalysis techniques
- Acute Lymphoblastic Leukemia research
- Lipid Membrane Structure and Behavior
- Complement system in diseases
- CAR-T cell therapy research
- Cancer-related molecular mechanisms research
- Nanoparticle-Based Drug Delivery
- Antimicrobial Peptides and Activities
- Venomous Animal Envenomation and Studies
- Transplantation: Methods and Outcomes
- HIV/AIDS drug development and treatment
- Nanoplatforms for cancer theranostics
- ATP Synthase and ATPases Research
- SARS-CoV-2 and COVID-19 Research
- Calcium signaling and nucleotide metabolism
- Lung Cancer Research Studies
- Virus-based gene therapy research
- HIV, Drug Use, Sexual Risk
- Dendrimers and Hyperbranched Polymers
- Surfactants and Colloidal Systems
UNSW Sydney
2019-2025
Cancer Institute of New South Wales
2019-2024
Australian Research Council
2022
University of Technology Sydney
2019-2020
Children's Cancer Institute Australia
2019-2020
Institute for Bioengineering of Catalonia
2014-2018
Universitat de Barcelona
2013-2018
Barcelona Institute for Global Health
2015-2018
Institut de Nanociència i Nanotecnologia de la Universitat de Barcelona
2015-2017
Consorci d’Atenció Primària de Salut Barcelona Esquerra
2013
Standard of care therapies for children with acute myeloid leukemia (AML) cause potent off-target toxicity to healthy cells, highlighting the need develop new therapeutic approaches that are safe and specific cells. Long non-coding RNAs (lncRNAs) an emerging highly attractive target in treatment cancer due their oncogenic functions selective expression However, lncRNAs have historically been considered 'undruggable' targets because they do not encode a protein product. Here, we describe...
High-risk childhood leukemia has a poor prognosis because of treatment failure and toxic side effects therapy. Drug encapsulation into liposomal nanocarriers shown clinical success at improving biodistribution tolerability chemotherapy. However, enhancements in drug efficacy have been limited lack selectivity the formulations for cancer cells. Here, we report on generation bispecific antibodies (BsAbs) with dual binding to leukemic cell receptor, such as CD19, CD20, CD22, or CD38, methoxy...
Introduction: Despite improvements in chemotherapy and molecularly targeted therapies, the life expectancy of patients with advanced non-small cell lung cancer (NSCLC) remains less than 1 year. There is thus a major global need to advance new treatment strategies that are more effective for NSCLC. Drug delivery using liposomal particles has shown success at improving biodistribution bioavailability chemotherapy. Nevertheless, drugs lack selectivity cells have limited ability penetrate tumor...
Combination therapies, where two drugs acting through different mechanisms are administered simultaneously, one of the most efficient approaches currently used to treat malaria infections. However, pharmacokinetic profiles often exhibited by combined tend decrease treatment efficacy as compounds usually eliminated from circulation at rates. To circumvent this obstacle, we have engineered an immunoliposomal nanovector encapsulating hydrophilic and lipophilic in its lumen lipid bilayer,...
Objectives The aim of the study was to compare prospectively indicator‐condition ( IC )‐guided testing versus those with non‐indicator conditions NIC s) in four primary care centres PCC B arcelona, S pain. Methods From O ctober 2009 F ebruary 2011, patients aged from 18 65 years old who attended a for new herpes zoster infection, seborrhoeic eczema, mononucleosis syndrome or leucopenia/thrombopenia were included group, and one every 10 randomly selected consulting other reasons group. A...
Abstract The spread of artemisinin-resistant parasites could lead to higher incidence patients with malaria complications. However, there are no current treatments that directly dislodge sequestered from the microvasculature. We show four common antiplasmodial drugs do not disperse rosettes (erythrocyte clusters formed by parasites) and therefore develop a cell-based high-throughput assay identify potential rosette-disrupting compounds. A pilot screen 2693 compounds identified Malaria Box...
Understanding how polyprotic compounds distribute within liposome (LP) suspensions is of major importance to design effective drug delivery strategies. Advances in this research field led the definition LP-based active encapsulation methods driven by transmembrane pH gradients with evidenced efficacy management cancer and infectious diseases. An accurate modeling membrane-solution partitioning also fundamental when designing systems for poorly endocytic cells, such as red blood cells (RBCs),...
New biomarkers have to be developed in order increase the performance of current antigen-based malaria rapid diagnosis. Antibody production often involves use laboratory animals and is time-consuming costly, especially when target Plasmodium , whose variable antigen expression complicates development long-lived biomarkers. To circumvent these obstacles, we applied Systematic Evolution Ligands by EXponential enrichment method identification DNA aptamers against falciparum -infected red blood...
Patients whose leukemias harbor a rearrangement of the Mixed Lineage Leukemia (MLL/KMT2A) gene have poor prognosis, especially when disease strikes in infants. The clinical outcome linked to this aggressive and detrimental treatment side-effects, particularly children, warrant urgent development more effective cancer-selective therapeutics. aim study was identify novel candidate compounds that selectively target KMT2A-rearranged (KMT2A-r) leukemia cells. A library containing 3707 approved...
Abstract Introduction: Standard of care therapies for children with acute myeloid leukemia (AML) cause potent off-target toxicity to healthy cells, highlighting the need develop new therapeutic approaches that are safe and specific cells. Long non-coding RNAs (lncRNAs) an emerging highly attractive target in treatment cancer due their oncogenic functions selective expression However, lncRNAs have historically been considered ‘undruggable’ targets because they do not encode a protein product....